WallStSmart

Castle Biosciences Inc (CSTL)vsIDEXX Laboratories Inc (IDXX)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

IDEXX Laboratories Inc generates 1136% more annual revenue ($4.66B vs $377.13M). IDXX leads profitability with a 25.4% profit margin vs -6.1%. IDXX earns a higher WallStSmart Score of 61/100 (C+).

CSTL

Avoid

34

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 6.7Quality: 8.5
Piotroski: 3/9Altman Z: 3.11

IDXX

Buy

61

out of 100

Grade: C+

Growth: 6.7Profit: 10.0Value: 2.7Quality: 7.0
Piotroski: 6/9Altman Z: 5.92
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CSTLUndervalued (+59.1%)

Margin of Safety

+59.1%

Fair Value

$79.14

Current Price

$32.75

$46.39 discount

UndervaluedFair: $79.14Overvalued
IDXXSignificantly Overvalued (-45.1%)

Margin of Safety

-45.1%

Fair Value

$447.14

Current Price

$700.65

$253.51 premium

UndervaluedFair: $447.14Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CSTL4 strengths · Avg: 9.0/10
Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
3.1110/10

Safe zone — low bankruptcy risk

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
23.9%8/10

Revenue surging 23.9% year-over-year

IDXX5 strengths · Avg: 9.6/10
Return on EquityProfitability
63.3%10/10

Every $100 of equity generates 63 in profit

Operating MarginProfitability
33.1%10/10

Strong operational efficiency at 33.1%

Altman Z-ScoreHealth
5.9210/10

Safe zone — low bankruptcy risk

Market CapQuality
$55.67B9/10

Large-cap with strong market position

Profit MarginProfitability
25.4%9/10

Keeps 25 of every $100 in revenue as profit

Areas to Watch

CSTL4 concerns · Avg: 2.5/10
Market CapQuality
$1.05B3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-4.1%2/10

ROE of -4.1% — below average capital efficiency

EPS GrowthGrowth
-51.6%2/10

Earnings declined 51.6%

IDXX3 concerns · Avg: 2.0/10
PEG RatioValuation
3.142/10

Expensive relative to growth rate

P/E RatioValuation
47.6x2/10

Premium valuation, high expectations priced in

Price/BookValuation
29.5x2/10

Trading at 29.5x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : CSTL

The strongest argument for CSTL centers on Debt/Equity, Altman Z-Score, Price/Book. Revenue growth of 23.9% demonstrates continued momentum.

Bull Case : IDXX

The strongest argument for IDXX centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 25.4% and operating margin at 33.1%.

Bear Case : CSTL

The primary concerns for CSTL are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : IDXX

The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 47.6x leaves little room for execution misses.

Key Dynamics to Monitor

CSTL profiles as a growth stock while IDXX is a mature play — different risk/reward profiles.

IDXX carries more volatility with a beta of 1.54 — expect wider price swings.

CSTL is growing revenue faster at 23.9% — sustainability is the question.

IDXX generates stronger free cash flow (421M), providing more financial flexibility.

Bottom Line

IDXX scores higher overall (61/100 vs 34/100), backed by strong 25.4% margins. CSTL offers better value entry with a 59.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Castle Biosciences Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Castle Biosciences Inc. is a pioneering diagnostics firm that enhances patient care through advanced gene-expression profiling tests, particularly within the skin cancer sector, exemplified by its flagship product, DecisionDx®-Melanoma. This innovative test offers essential insights for risk stratification, enabling oncologists to make informed treatment decisions in managing melanoma. With a strong focus on precision medicine, coupled with an extensive research and development strategy, Castle Biosciences is poised for growth as it seeks to expand its offerings and meet critical clinical demands. By addressing the complexities inherent in oncology, the company not only aims to improve patient outcomes but also to generate substantial value for its investors.

Visit Website →

IDEXX Laboratories Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.

Want to dig deeper into these stocks?